1. Home
  2. NGNE vs PBPB Comparison

NGNE vs PBPB Comparison

Compare NGNE & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • PBPB
  • Stock Information
  • Founded
  • NGNE 2003
  • PBPB 1977
  • Country
  • NGNE United States
  • PBPB United States
  • Employees
  • NGNE N/A
  • PBPB N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • PBPB Restaurants
  • Sector
  • NGNE Health Care
  • PBPB Consumer Discretionary
  • Exchange
  • NGNE Nasdaq
  • PBPB Nasdaq
  • Market Cap
  • NGNE 325.3M
  • PBPB 305.0M
  • IPO Year
  • NGNE N/A
  • PBPB 2013
  • Fundamental
  • Price
  • NGNE $18.48
  • PBPB $12.94
  • Analyst Decision
  • NGNE Strong Buy
  • PBPB Strong Buy
  • Analyst Count
  • NGNE 7
  • PBPB 2
  • Target Price
  • NGNE $41.86
  • PBPB $17.50
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • PBPB 257.0K
  • Earning Date
  • NGNE 08-11-2025
  • PBPB 08-06-2025
  • Dividend Yield
  • NGNE N/A
  • PBPB N/A
  • EPS Growth
  • NGNE N/A
  • PBPB N/A
  • EPS
  • NGNE N/A
  • PBPB 0.35
  • Revenue
  • NGNE N/A
  • PBPB $469,138,000.00
  • Revenue This Year
  • NGNE N/A
  • PBPB $5.28
  • Revenue Next Year
  • NGNE N/A
  • PBPB $4.30
  • P/E Ratio
  • NGNE N/A
  • PBPB $37.36
  • Revenue Growth
  • NGNE N/A
  • PBPB N/A
  • 52 Week Low
  • NGNE $6.88
  • PBPB $7.27
  • 52 Week High
  • NGNE $74.49
  • PBPB $13.67
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • PBPB 57.95
  • Support Level
  • NGNE $19.59
  • PBPB $12.78
  • Resistance Level
  • NGNE $20.46
  • PBPB $13.18
  • Average True Range (ATR)
  • NGNE 1.23
  • PBPB 0.38
  • MACD
  • NGNE -0.20
  • PBPB 0.05
  • Stochastic Oscillator
  • NGNE 13.37
  • PBPB 81.10

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About PBPB Potbelly Corporation

Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.

Share on Social Networks: